Similarly, in multiple animal models of Parkinson’s disease administration of the small molecule KV1.3 blocker PAP-1 inhibited degeneration of dopaminergic neurons and improved behavioral outcomes [8]. The gene discussed is KCNA3; the disease is Parkinson disease.